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Abstract 
Background: Cisplatin (CIS) is a potent antineoplastic agent with high therapeutic efficacy against many kinds of 
tumors. Its use is limited by its nephrotoxicity. The aim of this work was to minimize cisplatin effective dose and the 
possible reduction of its severe side effects. The present study was designed to assess the role of sulfur containing 
agent dimethyl sulfoxide (DMSO) on sensitization of mammary carcinoma, Ehrlich ascites carcinoma (EAC), to the 
action of cisplatin and at the same time the possible protective effect against cisplatin induced nephrotoxicity in 
experimental animals.
Methods: To evaluate these effects we have explored the cisplatin effect on the survival time of tumor‑bearing 
animals, tumor weight, cisplatin cellular uptake, apoptosis induction and cell cycle distribution and renal function in 
presence and absence of DMSO.
Results: Cisplatin at dose of 4.5 mg/kg increased the mean survival time of tumor bearing mice to 37 days compared 
with tumor bearing control mice. Pretreatment of tumor bearing mice with DMSO 50 % (2 ml/kg equal to 1 gm/kg) 
2 h. before cisplatin showed a significant increase in their mean survival time 43 days compared to cisplatin treated 
animals. DMSO pretreatment retained rat’s serum urea and creatinine levels to normal compared to animals treated 
with cisplatin alone.
Conclusion: DMSO pretreatment enhanced the cytotoxic activity of cisplatin against the growth of EAC in vivo and 
showed protective effects against cisplatin‑induce nephrotoxicity.
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Background
Cisplatin is one of the most active cytotoxic agents in 
clinical use that has proven efficacy against numerous 
human solid malignancies such as bladder, cervical, head 
and neck, esophageal, and small cell lung cancer [1]. 
However, some tumors such as colorectal and non-small 
cell lung cancers have intrinsic resistance to cisplatin, 
while others such as ovarian or small cell lung cancers 
develop acquired resistance after the initial treatment 
[2]. Recently, the cisplatin clinical usefulness is limited 
by chemoresistance and its side effects such as ototox-
icity and nephrotoxicity [3]. Chemosensitization is one 
strategy to overcome chemoresistance. It is based on the 
use of one drug or natural products to enhance the effi-
cacy of antineoplastic drugs by modulating one or more 
mechanisms of resistance. DMSO is an organo-sulfur 
compound with a reactive oxygen species scavenger [4]. 
Dimethyl sulfoxide has many chemical properties make 
it suitable as pharmaceutical carrier for many drugs, 
electrolytes and other molecules [5–7]. Uribe et  al. [8], 
found that DMSO treatment potentiated the effect of 
cisplatin and killed more sensory hair cells than treat-
ment with cisplatin alone. They interpreted their results 
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as DMSO could enhance cisplatin cytotoxicity by facili-
tating cisplatin entry into cells, increasing its intracellu-
lar concentration and likelihood of binding to DNA. In 
light of these findings the goal of this study is to examine 
the possible effect of DMSO pretreatment in enhancing 
the antitumor activity of CIS by examining CIS antitu-
mor activity, apoptosis induction, cell cycle distribution 
and cisplatin cellular uptake into tumor cells. In addition, 
examining the possible renal protective effect of DMSO 
against CIS triggered nephrotoxicity.
Methods
Drugs and chemicals
Cisplatin (CIS) and dimethylsulfoxide (DMSO) were 
purchased from Sigma Aldrich Co. (Saint Louis, Mis-
souri, USA). The stock solution of both drugs (dis-
solved in phosphate buffer saline (PBS) and preserved 
at −20  °C. The solutions were diluted in normal saline 
immediately before each experiment to the desired final 
concentration.
Animals and tumor
Female Swiss albino mice (8 weeks of age, 20–22 g body 
weight) and Female Wistar albino rats (8–10 weeks of age, 
180–200  g body weight) were obtained from King Fahd 
Medical Research center, King Abdulaziz University, Jed-
dah, Saudi Arabia. The animals were acclimatized for 
1 week before each experiment. A commercial balanced 
diet and water ad libitum were provided throughout the 
experiment. The Ehrlich ascites carcinoma cells (EAC) 
cells was obtained through the courtesy of National can-
cer institute (Cairo, Egypt) and maintained in our labo-
ratory by weekly I.P. transplantation of 2.5  ×  106 cells/
mouse. This study was approved by the Institutional ethi-
cal committee of King Abdulaziz hospital.
Evaluation of antitumor activity
The effect of DMSO on the antitumor activity of CIS 
against the growth of EAC was evaluated using the modi-
fied regimen of Donenko et  al. [9]. Ehrlich ascites car-
cinoma cells were inoculated i.p. into forty swiss albino 
mice (20–22 g) 2.5 × 106 cells/mouse. Twenty-four hours 
later, mice were equally divided into four groups. Group 
I injected with normal saline i.p. (0.2  ml/20 gm) and 
served as control group. Group II administered with CIS 
(4.5 mg/kg i.p.) while group III received a single dose of 
DMSO (50 %, 2 ml/kg i.p.). Group IV received DMSO fol-
lowed by cisplatin (4.5 mg/kg i.p.) 2 h later. Average sur-
vival days of mice and long term survivors are defined as 
the mice survived to the end of the experiment (45 days) 
with no apparent tumor.
Assessment of tumor weight
Ehrlich ascites carcinoma cells were collected from 
the ascitic fluid of female Swiss albino bearing mice 
8–10  days old ascites tumor. 1  ×  106 EAC cells were 
injected intramuscularly in right thigh of female Swiss 
albino mice selected for the experiment on day 0. The 
next day, animals were randomized and divided into four 
groups each treatment group contains 10 animals. Treat-
ment with DMSO and/or Cisplatin was proceed as the 
above paragraph.
On day 18, tumor bearing thigh of each animal was 
shaved and longest and shortest diameters of the tumor 
were measured with the help of Vernier Caliper. Tumor 
weight of each animal was calculated using the following 
formula:
The percent tumor growth inhibition was calculated on 
day 18 by comparing the average values of treated groups 
with that of tumor bearing control group.
Measurement of cisplatin cellular uptake
EAC were inoculated i.p. into 20 Swiss albino mice 
(20–22  g) 10  ×  106  cells/mouse. Twenty-four hours 
later mice were divided into two groups (10 mice each). 
Group I animals were treated with cisplatin (4.5 mg/kg, 
i.p.). Group II animals were treated with 50  % DMSO 
(2 ml/kg, i.p.) followed by cisplatin injection (4.5 mg/kg, 
i.p) 2  h. Later. Animals were sacrificed by cervical dis-
location 24 h. after treatment then the tumor cells were 
withdrawn and washed twice with PBS then the cells 
were counted. For drug uptake analysis, cells (1 × 106) 
were suspended in 1  % HNO3 for 24  h. at 70  °C to be 
digested. Lysed cells were analyzed by ICP-MS (Thermo 
scientific, iCAP 6000 series; USA). Provides a quantita-
tive analysis of the concentration of an element in aque-
ous solution [10].
Assay of apoptosis
Apoptosis cells were quantified by annexin V-FITC-pro-
podium iodide double staining, using an annexin V-FITC 
apoptosis detection kit. EAC were inoculated i.p. into 
40 Swiss albino mice (20–22  g) 10  ×  106 cells/mouse. 
Twenty-four hours later mice were divided into four 
groups (10 mice each). Group I animals were treated with 
normal saline i.p. (2  ml/kg, i.p.) and served as control 
group. Group II animals were treated with 50 % DMSO 
(2 ml/kg, i.p.). Group III animals were received cisplatin 
(4.5  mg/kg, i.p.). Group IV animals were treated with 
50 % DMSO (2 ml/kg, i.p.) followed by cisplatin (4.5 mg/
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Animals were sacrificed by cervical dislocation 24  h 
after treatment then the tumor cells were withdrawn 
and washed twice with PBS and resuspended in 100  µl 
annexin V incubation reagent prepared by mixing (bind-
ing buffer 10×, PI, annexin V-FITC and deionized water) 
for each sample. The solution was incubated in the dark 
for 15 min at RT. Then 400 μl 1× of binding buffer were 
added to each sample and process by flow cytometry 
(NAVIOS Beckman Coulter, USA) within 1  h for maxi-
mal signal.
Cell cycle analysis
Ehrlich ascites carcinoma cells were inoculated i.p. into 
sixty swiss albino mice (20–22  g) 10 ×  106 cells/mouse 
and processed as mentioned in the paragraph of Apop-
tosis. Tumor cells were obtained 24  h. after cisplatin 
treatment. Cell cycle analysis was performed using flow 
cytometer (Becto Dicknson, BD, FACScalbur, USA 
according to the method of Pozarowiski P., Darzynkie-
wicz [11].
Effect of CIS and/or DMSO on kidney function and renal 
histopathology
Twenty male wister rat were divided into four equal 
groups, 5 animals each. Group I animals were received 
normal saline i.p. (2 ml/kg, i.p.) and reserved as control 
group. Group II animals were treated with 50 % DMSO 
(2  ml/kg i.p.). Group III animals were treated with cis-
platin (7.5  mg/kg, i.p.). Finally, Group IV animals were 
treated with 50 % DMSO (2 ml/kg, i.p.) followed by cis-
platin (7.5 mg/kg, i.p.) 2 h later. At the end of the experi-
ment period (72  h), rats were anesthetized and blood 
samples were collected from the ophthalmic artery in the 
orbital rim and rapidly centrifuged for serum separation 
that was stored at −80 °C to evaluate serum urea and cre-
atinine levels.
The dissected rat kidney was cut into small pieces and 
immersed immediately in 10 % neutral buffered formalin, 
for light microscope study.
Evaluation of serum creatinine concentration
The serum creatinine concentration was estimated by 
alkaline picrate method using the commercially available 
kit [12].
Evaluation of serum urea concentration
The blood urea was estimated by Berthelot method [13] 
using the commercially available kit.
Statistical analysis
Statistical analysis was performed using SPSS (Statisti-
cal package of social science, version 16).One way anal-
ysis of variance (ANOVA) followed by least significant 
difference (LSD) for post hoc analysis was used for mul-
tiple comparisons. Statistical significance was acceptable 
to a level of p ≤0.05.
Results
Survival of tumor bearing mice
Table  1 shows the survival of Erlich ascites carcinoma 
bearing mice after treatment with cisplatin and/or 
DMSO. Tumor-bearing control mice showed a mean 
survival time of 17 days, whereas,administration of a sin-
gle dose of cisplatin (4.5 mg/kg, i.p.) increased the mean 
survival time to 37 days, with 50 % long term survivors. 
Treatment with 50  % DMSO 2  h. before increased the 
mean survival time of tumor-bearing mice to 43  days 
with 80 % survivors.
Assessment of tumor weight
Table  2 shows Anti-tumor efficacy of cisplatin and/or 
DMSO which was expressed as the percentage of tumor 
Table 1 Effects of  cisplatin and/or DMSO on  the survival 
time of mice bearing EAC cells
Data represent the mean ± SD of ten mice
a Significantly different from control at P value < 0.05)
b Significantly different from cisplatin at P value <0.05, one way ANOVA with 
LSD post test)




Normal saline (2 ml/kg) 17 ± 0.45 0
50 % DMSO (2 ml/kg) 18 ± 0.37 0
Cisplatin (4.5 mg/kg) 37 ± 3.41a 50
Cisplatin + 50 %  
DMSO (4.5 mg/ 
kg + 2 ml/kg)
43 ± 2.10a,b 80
Table 2 Average weights and  tumor inhibition of  ehrlich 
solid tumor 18 days after treatment
Ehrlich ascites carcinoma cells were injected intramuscularly in right thigh of 
female Swiss albino mice The next day, animals were randomized and divided 
into four groups each treatment group contains 10 animals. Group I injected 
with normal saline (2 ml/kg, i.p.) and served as control group. Group II treated 
with 50 % DMSO (2 ml/kg, i.p.). Group III treated with cisplatin (4.5 mg/kg, i.p.). 
Group IV treated with (2 ml/kg, i.p.) of 50 % DMSO followed by cisplatin (4.5 mg/
kg, i.p.) 2 h later. Each data represent the mean ± SEM
a Significantly different from normal saline treated group at P value <0.05
b Significantly different from cisplatin treated group at P value <0.05




Normal saline 910 ± 22.8 0
50 % DMSO 761 ± 17.1 16
Cisplatin (4.5 mg/kg) 352 ± 8.4a 61
50 % DMSO + Cisplatin 
(4.5 mg/kg)
180 ± 5.8a,b 80
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growth inhibition calculated on day 18 by comparing 
the average tumor weight of treated groups with that of 
tumor bearing control group. Tumor growth in saline 
treated animals was taken to be 100  %. Cisplatin treat-
ment (4.5  mg/kg, i.p.) showed 61  % inhibition of tumor 
growth. Pretreatment with DMSO 50  % (2  ml/kg, i.p.) 
showed 80 % inhibition of growth of solid EAC.
Effect of cisplatin and/or DMSO on apoptosis induction 
in EAC cells
The percentage of early apoptotic cells (Annexin V-pos-
itive cells) were dramatically increased after treat-
ment with cisplatin in comparison to the control cells 
(% early apoptosis cells). Also, pretreatment with 50  % 
DMSO (2  ml/kg, i.p.) followed by cisplatin (4.5  mg/kg, 
i.p.) increased the percentage of early apoptotic cells 
(Annexin V-positive cells) significantly compared with 
EAC cells withdrawn from animals treated with cisplatin 
(4.5 mg/kg, i.p.) alone Fig. 1.
Effect of CIS and/or DMSO treatment on cell cycle phase 
progression in ehrlich cells
Figure 2 shows the percent distribution of G0/G1, S, and 
G2/M of tumor cells 24  h after treatment with cisplatin 
and/or DMSO. Cisplatin treatment (4.5 mg/kg, i.p.) accu-
mulated the cells in G0/G1 phase by 42 %. Pretreatment 
with 50  % DMSO (2  ml/kg, i.p.) followed by cisplatin 
(4.5  mg/kg, i.p.) significantly increase the accumulation 
in G0/G1 phase by 57 %.
Cisplatin cellular uptake in Ehrlich ascites cells
Table 3 shows the cellular level of CIS in Ehrlich ascites 
cells after a single dose of cisplatin (4.5 mg/kg, i.p.) and/
or DMSO 2  h before (50  %, 2  ml/kg, i.p.). All the time 
Fig. 1 Effect of cisplatin and/or DMSO on apoptosis induction in EAC cells withdrawn 24 h. after treatment. Apoptosis was analyzed by staining 
with propiduim iodide (PI, y-axis) and annexin—FITC (x-axis). a EAC cells withdrawn from normal saline (2 ml/kg, i.p.) treated animals. b EAC cells 
withdrawn from animals treated with 50 % DMSO (2 ml/kg, i.p.). c EAC cells withdrawn from animals treated with cispalin (4.5 mg/kg, i.p.) alone. d 
EAC cells withdrawn from animals pretreated with 50 % DMSO (2 ml/kg, i.p.) followed by cispatin (4.5 mg/kg, i.p.). The percentage of cells in each 
quadrant is indicated (R1 necrosis, R2 late apoptosis, R3 live Cells, R4 early apoptosis). The experiment was repeated twice each one in duplicate
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point tested showed that DMSO pretreatment increased 
the cellular uptake of CIS in the tumor cells (Table 3).
Effects of DMSO on cisplatin induced‑nephrotoxicity
Table  4 represents the kidney function (serum creati-
nine and urea) of treated animals. DMSO treatment had 
no significant effect on urea and serum creatinine levels 
compared with control group. Serum urea and creati-
nine average levels were significantly elevated in cisplatin 
treated animals by about 237 and 3  mg/dl, respectively. 
While DMSO pretreatment of cisplatin treated animals 
return both urea and creatinine levels nearly to normal 
values (73 and 0.73 mg/dl, respectively).
Figures (3, 4) showed normal kidney tissue with no 
abnormalities when the animals treated with normal 
saline or DMSO, respectively. While treatment with cis-
platin (7.5 mg/kg, i.p.), there were marked necrosis in 
proximal tubules and degeneration of the tubular epi-
thelial cells (Fig.  5). Pretreatment with 50  % DMSO(2 
ml/kg, i.p.), decreased the cisplatin induced tubu-
lar necrosis (Fig.  6) comparing with cisplatin treated 
animals. 
Discussion
Cisplatin is the most widely used cytotoxic drug in the 
treatment of many kinds of tumors either alone or in com-
bination with other cytocidal agents. However, its clinical 
uses are limited by its detrimental adverse effects includ-
ing nephrotoxicity. Chemosensitization is one strategy that 
may be used to decrease the anti-tumor dose and toxicity. 
A variety of approaches have been tried to enhance the 
cytotoxic effects of chemotherapeutic agents and at the 
same time decreased their toxicity. Among the potential 
chemosensitizer is dimethyl sulfoxide which has chemo-
preventive [14] and cytotoxic activity [15]. This study 
focused on investigating whether DMSO would enhance 
the cisplatin cytotoxic effects against the growth of EAC 
cells in vivo and the possible protective effect against cis-
platin induced nephrotoxicity. The possible modulatory 
mechanisms were also explored by studying the changes of 
apoptosis induction, cell cycle phase distribution and cis-
platin cellular uptake after treatment with cisplatin in the 
presence and absence of DMSO. Preliminary studies with 
different DMSO doses showed that a dose level of 2 ml/kg 
(2 gm/kg) was of great efficacy and little organ toxicity.
Fig. 2 Effect of cisplatin and/or DMSO on cell cycle phase distribution of EAC cells after 24 h of treatment. Cell cycle distribution was analyzed 
by staining with propidium iodide (PI). a Cells that withdrawn from animals treated with normal saline (2 ml/kg, i.p.), b cells that withdrawn from 
animals treated with cisplatin (4.5 mg/kg, i.p.). c Cells that withdrawn from animals pretreated with 50 % DMSO (2 ml/kg, i.p.) followed by Cisplatin 
(4.5 mg/kg, i.p.). d Cells withdrawn from animals treated with 50 % DMSO (2 ml/kg, i.p.). The experiment was repeated twice
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The current study showed that the pretreatment of 
tumor bearing mice with 50  % DMSO (2  ml/kg, i.p.), 
significantly enhances the cytotoxic activity of cisplatin 
against the growth of EAC cells by 1.6-fold increase in 
the long term survivor compared with animals treated 
with cisplatin alone (Table 1).
Table 3 Effect of DMSO pretreatment on the cellular uptake of cisplatin in EAC cells using ICP-MS
Cisplatin was injected (4.5 mg/kg, i.p.) in tumor-bearing mice pretreated with DMSO (2 ml/kg, i.p.) or saline. After 6, 24 and 48 h of treatment, cells were withdrawn 
and washed twice with PBS, counted then digested by using 1 % nitric acid. Data are expressed as mean ± S.E.M (n = 10)
a Significantly different from corresponding CIS at P value <0.05
Cisplatin concentration (ng/106 cells)
6 h after treatment 24 h after treatment 48 h after treatment
Cisplatin (4.5 mg/kg) 7 ± 0.26 14 ± 0.47 18 ± 0.58
Cisplatin (4.5 mg/kg) and 50 % DMSO (2 ml/kg) 15 ± 0.23 a 28 ± 0.45a 35 ± 1.25a
Table 4 Effect of  treatment with  cisplatin and/or DMSO 
on serum urea and creatinine levels
Values are expressed in mean ± SEM (n = 5)
a Significantly different from control at P value <0.05
b Significantly different from CIS at P value <0.05, one way ANOVA with LSD 
post test
Treated groups Parameters
Urea (mg/dl) Creatinine (mg/dl)
Normal saline 48 ± 1.7 0.51 ± 0.02
50 % DMSO 52 ± 0.49 0.54 ± 0.04
Cisplatin 237 ± 11.51a 3 ± 0.25a
Cisplatin and 50 % DMSO 73 ± 3.44a,b 0.73 ± 0.11a,b
Fig. 3 A photomicrograph of a section of rat kidney from control 
group treated with normal saline (2 ml/kg, i.p.) showing proximal con‑
voluted tubules (black arrows) having cuboidal cells with eosinophilic 
cytoplasm and round nuclei situated in the center or near the base 
of the cells. The distal convoluted tubules (white arrows) also reveal 
eosinophilic cuboidal cells with round nuclei. Glomeruli: G (H&E 
×400)
Fig. 4 A photomicrograph of a section of rat kidney treated with 
50 % DMSO (2 ml/kg, i.p.) showing well organized architecture. The 
epithelium of most of the proximal (black arrows) and distal convo‑
luted tubules (white arrows) show normal structure. Glomerulu: G. 
(H&E ×400)
Fig. 5 A photomicrograph of a section of rat kidney treated with 
cisplatin (7.5 mg/kg, i.p.) showing disruption of epithelium of the 
proximal convoluted tubule (thick black arrow) and distal convoluted 
tubule (white arrow). Karyorrhetic nuclei within the vacuolated cyto‑
plasm of the tubular epithelium (dashed arrows) are observed. (filled 
star) Pyknotic nuclei are noticed (thin black arrows) in the endothelial 
and mesangial cells of the glomerulus (G). Dilated congested blood 
vessels (bv) and intertubular capillaries are also noticed (H&E ×400)
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It is well known that cisplatin induced formation of intra 
and inter-DNA strand cross linkage lead to severe local 
distortion in the DNA double helical structure lead to cell 
death [16–18]. For more conformation, the study showed 
that the treatment of solid Ehrlich tumor bearing mice 
with 50 % DMSO before cisplatin treatment increased the 
percentage of inhibition of solid tumor growth to 80  % 
compared with 61 % in cisplatin treated animals (Table 2).
The above mentioned results have been confirmed 
by the observed increase in cisplatin cellular uptake 
after DMSO treatment. Pretreatment with DMSO lead 
to almost twofolds increase in the cisplatin accumula-
tion ratios in EAC cells compared with correspond-
ing cells treated with cisplatin alone (Table  3). It has 
been reported that DMSO induces membrane thinning, 
increases the fluidity of the membrane hydrophobic core 
and induces transient water pores into the membrane 
which may facilitate the uptake of cisplatin into tumor 
cells [5, 19, 20]. This may lead to more cisplatin uptake 
and consequently lead to cell death. The current study 
agree with that reported by Uribe et  al. [8], who found 
that DMSO treatment potentiated the effect of cisplatin 
and killed more sensory hair cells than treatment with 
cisplatin alone. They also interpreted their results as 
DMSO could enhance cisplatin cytotoxicity by facilitat-
ing cisplatin entry into cells, increasing its intracellular 
concentration and likelihood of binding to DNA. This 
finding has been observed in our study where DMSO 
treatment increased cellular uptake and cytotoxicity of 
cisplatin against the growth of tumor cells. DMSO may 
bind to cisplatin after tumor cell entry, where cisplatin-
DMSO adducts have greater affinity for DNA, potentiat-
ing cisplatin cytotoxicity [21]. Also, our results supports 
Pommier et al. [22] who reported that DMSO could sen-
sitize cancer cells to the apoptosis or growth arrest and 
synergistically increases the cytotoxicity of antineoplastic 
agents against five different human tumor reference cell 
lines. Moreover, our results showed a significant increase 
in percentages of early apoptosis in the EAC cells treated 
with cisplatin and DMSO, compared with cells treated 
with cisplatin alone (Fig. 1).
In contrary to our previous results, Hall et  al. [23] 
showed inhibition of cytotoxicity and ability to initiate 
cell death when cisplatin dissolved in DMSO. This dis-
crepancy could be refuted as their study depended on 
formation of new chemical compound between cisplatin 
and DMSO, while the principle of our study depends on 
pretreatment of animals with DMSO before cisplatin. 
This preempt administration allowed DMSO to distrib-
ute into EAC cells and to exerts its possible modulation 
effect on different targets such as cell membrane and 
mitochondrial membranes, apoptotic signaling proteins 
and cell cycle regulators. The current results showed 
that the pretreatment of the tumor cells withdrawn from 
animals treated with DMSO before cisplatin, showed a 
significant increase in the arrested cells in G0 compared 
with cells treated with cisplatin alone (Fig. 2). This could 
be due to the capability of DMSO to modulate several cell 
signaling molecules, including cell survival proteins, drug 
transporters and cell proliferative proteins and its abil-
ity to interfere with the expression of anti-apoptotic sig-
nals [15, 24]. It is well known that DNA damage caused 
by different cytotoxic agents, induced cell cycle arrest at 
G1, S, G2, thereby preventing replication of damaged DNA 
or aberrant mitosis which if not repaired, may result in 
either tumorigenesis or apoptosis [15]. Our results sug-
gested that DMSO induce apoptosis dominantly in a wide 
variety of tumor cells through targeting many of the cispl-
atin apoptotic protein as overexpression of P53 [25], P21 
[26], Bcl-2 and Bcl2/bax ratio [27] This will able DMSO 
to potentiate the cisplatin induced-apoptosis and lead to 
more killing effect. In animals studies the acute nephro-
toxicity induced by cisplatin was associated with high 
level of serum creatinine and blood urea nitrogen [28].
In the current study, rats treated with cisplatin alone 
showed a significant increase in the levels of serum creati-
nine and blood urea levels, while in the DMSO pretreated 
animals the levels nearly return to normal (Table 4).
Previous results by Ali and Mousa, [28] have also 
reported that DMSO was effective in completely pre-
venting the development of signs of nephrotoxicity of 
nephrotoxic drug gentamycin (50 mg/kg), in treated rats. 
Fig. 6 A photomicrograph of a section of rat kidney treated with 
cisplatin (7.5 mg/kg, i.p.) after 2 h of pretreatment with 50 % DMSO 
(2 ml/kg, i.p.) showing most of the proximal convoluted tubules (thick 
black arrow) and distal convoluted tubules (white arrow) revealing 
normal tubular epithelium. Few reveal attenuated and desquamated 
epithelium (white circle). Others contain intra‑tubular pink homog‑
enous casts (thin black arrows) (H&E ×400)
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In harmonization with our results they stated that treat-
ment with DMSO alone did not alter significantly any of 
the renal function tests studied. Our biochemical results 
have been confirmed by histopathological studies of the 
kidneys of cisplatin treated rats in presence and absence 
of DMSO. Histopatholgical evaluation in this study 
showed that cisplatin treatment causes a marked necrosis 
in proximal tubules and degeneration of the tubular epi-
thelial cells, while pre-treatment with DMSO minimized 
these histopathological deteriorations (Figs. 5, 6). Moreo-
ver, electron microscopic investigation of rat’s kidneys 
tissues after cisplatin treatment in presence and absence 
of DMSO confirmed the histopathological findings (data 
not shown). These results are in a good agreement with 
Jones et  al. [12, 14] and Santos et  al. [29] who reported 
the protective effect of DMSO against cisplatin-induced 
kidney tissues damage. They referred this protective 
effect to antioxidant properties of DMSO which result in 
reserving glutathione and consequently introduce a per-
fect nephroprotection.
In conclusion, it seems that dimethyl sulfoxide could 
potentiate the cytotoxic activity of cisplatin by many dif-
ferent molecular mechanisms which need to be carefully 
investigated to know the exact mechanisms of synergistic 
interaction between DMSO and cispaltin. Also DMSO 
could be a proper agent to be applied clinically in many 
other situations with a dose up to one gram per kilogram 
body weight.
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